Medidata Solutions to Participate in Three Investor Conferences in September 2012

NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based clinical development solutions, today announced that Chairman and CEO Tarek Sherif, President Glen de Vries, and Chief Financial Officer Cory Douglas will participate in three upcoming investor conferences in September.

Deutsche Bank 2012 Technology Conference
Date:	September 12, 2012, 9:30 am PT
Location:	Las Vegas, NV
Participants:	Tarek Sherif and Cory Douglas
ThinkEquity's 9th Annual Growth Conference (G9)
Date:	September 13, 2012, 3:30 pm ET
Location:	New York, NY
Participants:	Tarek Sherif and Cory Douglas
Credit Suisse 3rd Annual Small and Mid Cap Conference
Date:	September 21, 2012, 9:20 am ET
Location:	New York, NY
Participants:	Glen de Vries and Cory Douglas

Live audio webcasts will be available for the Deutsche Bank 2012 Technology Conference and ThinkEquity’s 9^th Annual Growth Conference on the “Investor” section of Medidata’s website at http://investor.mdsol.com. Please visit the website at least 15 minutes prior to each event to register, download and install any necessary audio or video software to access the presentation. For those unable to participate in the live webcasts, replays will be archived on the “Investor” section of Medidata’s website at http://investor.mdsol.com for a limited period of time following the conferences.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.